GlassScriptPhysician profile
David R Zimmerman
NPI 1255744777
$7,770.15
in general payments reported to CMS, 2019-2025
25 companies · $685 in 2025
The $685 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,698 · 2020: $860 · 2021: $1,575 · 2022: $833 · 2023: $545 · 2024: $574 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,138.25 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Glaukos Corporation | $1,244.87 | 2021-2025 | Photrexa Viscous and Photrexa, Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $823.77 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $557.64 | 2019-2023 | Acuvue |
| Abbvie INC. | $425.16 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $299.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $270.08 | 2019-2023 | |
| Oyster Point Pharma, INC. | $255.49 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $245.56 | 2020-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $240.73 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $225.92 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $217.07 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $145.15 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $105.67 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $103.84 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $88.75 | 2019-2020 | |
| Biotissue Holdings INC. | $79.44 | 2020-2024 | |
| Kala Pharmaceuticals, INC. | $78.04 | 2021 | |
| Mallinckrodt Enterprises LLC | $63.41 | 2019 | |
| Shire North American Group INC | $46.70 | 2019 | |
| Alcon Research LLC | $38.73 | 2019 | |
| Ocular Therapeutix, INC. | $29.47 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $20.56 | 2021 | |
| Rxsight INC | $20.31 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Maculogix, INC. | $6.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.